Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Ulf LindströmBente GlintborgDaniela Di GiuseppeDan NordströmSella Aarrestad ProvanBjorn GudbjornssonJohan AsklingMerete Lund HetlandKalle AaltonenNiels Steen KroghArni Jon GeirssonLennart T H JacobssonPublished in: RMD open (2019)
This observational study of biologics-naïve patients with SpA from five Nordic countries showed similar baseline characteristics and very similar retention rates in patients treated with originators versus biosimilars, for both infliximab and etanercept, indicating comparable effectiveness in clinical practice.